ICON

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ICON (ICLR) reports robust earnings, eyes strategic partnerships for growth

ICON's Q4 2022 earnings reflect strong financial performance and strategic advancements. While facing challenges in pricing and COVID-related headwinds, the company is well-positioned to capitalize on growth opportunities through margin maintenance, strategic partnerships, and M&A focus.

ICON (ICLR) reports stable Q1 earnings, eyes growth amid challenges

ICON's Q1 2023 earnings call highlighted solid financial performance, strategic partnerships, and investments in innovation. While facing challenges in pricing negotiations and biotech funding, the company remains resilient and focused on growth opportunities. Stabilizing backlog burn rates, leveraging innovative tools, and addressing labor market dynamics present avenues for future success.

ICON reports solid Q2 performance and eyes growth opportunities

ICON's Q2 performance reflects growth momentum and strong financial outlook for 2023. Challenges include growth uncertainty and revenue predictability amid customer fluctuations. Opportunities lie in strategic partnerships, margin improvement, and market expansion.

ICON (ICLR) posts robust Q3 results, eyes growth amid challenges

ICON (ICLR) reports strong Q3 earnings, emphasizing revenue growth, strategic partnerships, and operational improvements. The company faces challenges from macroeconomic factors and customer concentration but sees opportunities in RFP growth and R&D budget expansion. With a focus on innovation and adaptability, ICON aims to maintain its strong performance and capitalize on future opportunities.

ICON (ICLR) reports strong Q4 earnings, eyes strategic growth

ICON's strong performance in Q4 and 2023 driven by revenue growth and margin improvement
Challenges include customer concerns over R&D spend and wide revenue guidance range for 2024
Opportunities lie in new partnerships, automation for margin expansion, and capital deployment priorities
Overall, ICON remains competitive, with positive outlook for future growth and development

ICON (ICLR) reports strong Q1 earnings and strategic growth outlook

ICON (ICLR) delivered a strong performance in Q1 2024, with robust financial results, strategic initiatives, and updated guidance reflecting confidence in future prospects.
While facing challenges such as revenue fluctuations and analyst inquiries, the company's strengths in client engagement, operational efficiency, and market positioning provide a solid foundation for growth.
Opportunities in M&A, customer base diversification, and data strategy underscore potential avenues for expansion and innovation, positioning ICON well for continued success in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the development, management and analysis of programs that support clinical development. It operates through the following geographical segments: Ireland, Rest of Europe, U.S. and Other. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

DUBLIN--(BUSINESS WIRE)-- #DCTs--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its Digital Platform. The platform supports seamless integration of ICON patient, site and sponsor services with the delivery of harmonised data and can be customised for any study design, from traditional to fully decentralised, and for any therapeutic area. The ICON Digital Platform is an end-to-end solution that enables patient se.

ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform

DUBLIN--(BUSINESS WIRE)--ICON plc set to join Russell 3000® Index.

ICON plc Set to Join Russell 3000® Index

ICON PLC shares set higher lows in June, and the company presents strong fundamentals and economic earnings for shareholders. ICLR has shown robust financial performance, with a 9% YoY increase in revenue and a 200bps expansion in gross margin YoY. I reiterate ICLR as a buy, revising the price target to $304, and keeping the long-term $326 target.

ICON PLC: Disconnect From Fundamentals, Unfairly Punished

DUBLIN--(BUSINESS WIRE)--ICON plc to Attend Upcoming Investor Conferences.

ICON plc to Attend Upcoming Investor Conferences

ICON Public Limited Company (ICLR) Q1 2023 Earnings Call Transcript.

ICON Public Limited Company (ICLR) Q1 2023 Earnings Call Transcript

Icon PLC (ICLR) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.76 per share a year ago.

Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates

DUBLIN--(BUSINESS WIRE)--ICON Reports First Quarter 2023 Results.

ICON Reports First Quarter 2023 Results

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules First Quarter 2023 Earnings Conference Call

ICON plc Schedules First Quarter 2023 Earnings Conference Call

Danaher

Icon's double digit earnings growth forecast should drive its stock price. IQVIA's increased operational efficiency and earnings growth should drive its share price.

2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to Watch

CRH PLC

Diageo

Flutter Entertainment PLC

Ryanair Hlds

For St. Patrick's Day, you might crack open a Guinness brewed by Diageo PLC (NYSE: DEO). If that inspires you to investigate how Irish stocks may fit into your portfolio, you have quite a few to choose from.

Should You Bring The Luck Of The Irish To Your Investmets?

BALLERUP, Denmark & DUBLIN--(BUSINESS WIRE)-- #partnership--LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company's overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

One name particularly appealing in the healthcare space is ICON Public Limited Company, a CRO (Contract Research Organization) that has delivered sustained revenue growth. While the macroeconomic environment is still unclear, the outlook for ICON seems fairly stable, with EBITDA margin expanding and EPS seen to grow at a solid pace in 2023.

ICON: Attractive Valuation, Earnings Growth Driving Future Outperformance

ICON Public Limited Company (NASDAQ:ICLR ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Kate Haven - VP of IR Brendan Brennan - CFO Steve Cutler - CEO Conference Call Participants Sandy Draper - Guggenheim Justin Bowers - Deutsche Bank Patrick Donnelly - Citi Eric Coldwell - Baird Casey Woodring - JPMorgan David Windley - Jefferies Elizabeth Anderson - Evercore Dan Leonard - Credit Suisse Jack Meehan - Nephron Research Derik De Bruin - Bank of America Operator Good day and thank you for standing by. Welcome to the ICON Q4 and Full Year 2022 Earnings Conference Call.

ICON Public Limited Company (ICLR) Q4 2022 Earnings Call Transcript

Icon PLC (ICLR) delivered earnings and revenue surprises of 2.29% and 0.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Surpasses Q4 Earnings and Revenue Estimates

DUBLIN, Ireland--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2022 Results

ICON Reports Fourth Quarter and Full Year 2022 Results

CarGurus

Chord Energy Corp

Darling Ingredients

MasTec

ServiceNow

Planet Fitness

S&P Global

Vici Properties

A sharp selloff in growth stocks creates opportunity for keen investors. Here are nine top-rated picks to consider.

The 9 Best Growth Stocks to Buy Right Now

Icon PLC (ICLR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Icon PLC (ICLR) is Poised to Beat Earnings Estimates Again

Axcelis Technologies

Catalyst Pharmaceuticals

Lattice Semiconductor

Performance Food Group

The search for growth stocks, or companies with high potential for future growth, is on. These growth stocks often represent young, rapidly-expanding companies that are reinvesting their earnings back into their core business.

The 7 Best Growth Stocks to Buy for February 2023

ICON plc has set new highs after re-rating to the upside from late FY22. The company posted FY23E' guidance in January, where investors were swift to price in the growth forecasts.

ICON plc: Market Repricing Higher, Revising To Buy At 33x Forward P/E

DUBLIN--( BUSINESS WIRE )-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the fourth quarter 2022 after the market closes on Wednesday, February 22, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 23, 2023 at 8:00am ET.

ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call

DUBLIN--( BUSINESS WIRE )-- ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023. For the full year 2023, revenue is expected to be in the range of $7,940 - $8,340 million, representing growth of 3.3% – 6.8%, and adjusted earnings per share1 is expected to be in the range of $12.40 – $13.05, representing growth of 6.4% – 10.1%, over Full Year 2022 revenue and adjusted earnings per share guidance, respectively.

ICON Issues Financial Guidance for Full Year 2023

DUBLIN, Ireland--( BUSINESS WIRE )--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 5:15pm PST/ 8.15pm EST.

ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference

DUBLIN--( BUSINESS WIRE )--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others

Williams-Sonoma

TROY, Mich. , Nov. 28, 2022 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Icon PLC (NYSE: ICLR) as its "Stock to Study" and Williams-Sonoma Inc. (NYSE: WSM) as its "Undervalued Stock" in the January-February 2023 issue for investors' informational and educational use.

BetterInvesting™ Magazine Update on Icon PLC and Williams-Sonoma Inc.

DUBLIN--( BUSINESS WIRE )--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022. The presentation will be webcast live from 08:00am EST.

News for ICON Stock (ICLR)